Market Closed -
Nasdaq
04:00:00 2024-05-01 pm EDT
|
5-day change
|
1st Jan Change
|
25.82
USD
|
+1.89%
|
|
+0.70%
|
+39.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
266.4
|
486.4
|
235.8
|
210.7
|
212.5
|
300.4
|
-
|
-
|
Enterprise Value (EV)
1 |
266.4
|
486.4
|
235.8
|
210.7
|
212.5
|
300.4
|
300.4
|
300.4
|
P/E ratio
|
-119
x
|
56.6
x
|
32.1
x
|
-9.29
x
|
-4.58
x
|
-10.8
x
|
-15.4
x
|
-27.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.5
x
|
16.6
x
|
6.18
x
|
35
x
|
44.7
x
|
21.5
x
|
12.7
x
|
8.65
x
|
EV / Revenue
|
14.5
x
|
16.6
x
|
6.18
x
|
35
x
|
44.7
x
|
21.5
x
|
12.7
x
|
8.65
x
|
EV / EBITDA
|
-69
x
|
39.1
x
|
13.4
x
|
-12.1
x
|
-5.19
x
|
-16.1
x
|
-19.5
x
|
-50.1
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,758
|
11,022
|
11,311
|
11,451
|
11,488
|
11,635
|
-
|
-
|
Reference price
2 |
27.30
|
44.13
|
20.85
|
18.40
|
18.50
|
25.82
|
25.82
|
25.82
|
Announcement Date
|
3/10/20
|
3/10/21
|
3/8/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
18.37
|
29.38
|
38.16
|
6.027
|
4.758
|
14
|
23.57
|
34.73
|
EBITDA
1 |
-3.86
|
12.44
|
17.54
|
-17.41
|
-40.95
|
-18.7
|
-15.4
|
-6
|
EBIT
1 |
-3.885
|
12.42
|
17.53
|
-17.41
|
-41.85
|
-12.9
|
-8.35
|
-0.35
|
Operating Margin
|
-21.15%
|
42.25%
|
45.94%
|
-288.93%
|
-879.53%
|
-92.14%
|
-35.43%
|
-1.01%
|
Earnings before Tax (EBT)
1 |
-1.982
|
11.8
|
15.89
|
-17.12
|
-40.83
|
-24.85
|
-20.15
|
-10.85
|
Net income
1 |
-1.982
|
8.793
|
7.787
|
-22.58
|
-46.3
|
-27.57
|
-19.1
|
-10.9
|
Net margin
|
-10.79%
|
29.92%
|
20.41%
|
-374.58%
|
-973.16%
|
-196.9%
|
-81.05%
|
-31.38%
|
EPS
2 |
-0.2300
|
0.7800
|
0.6500
|
-1.980
|
-4.040
|
-2.383
|
-1.680
|
-0.9300
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/10/21
|
3/8/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.94
|
35.94
|
3.107
|
0.983
|
0.451
|
1.486
|
0.437
|
1.658
|
0.83
|
1.833
|
1.705
|
2.307
|
4.457
|
5.9
|
EBITDA
1 |
-1.345
|
30.37
|
-2.063
|
-4.766
|
-4.368
|
-6.21
|
-9.944
|
-5.732
|
-5.563
|
-19.71
|
-5.3
|
-5
|
-4.6
|
-3.8
|
EBIT
1 |
-3.345
|
30.36
|
-2.065
|
-4.767
|
-4.372
|
-6.21
|
-10.17
|
-5.957
|
-5.787
|
-19.93
|
-4.95
|
-4.3
|
-2.8
|
-0.9
|
Operating Margin
|
-355.85%
|
84.48%
|
-66.46%
|
-484.94%
|
-969.4%
|
-417.9%
|
-2,327.23%
|
-359.29%
|
-697.23%
|
-1,087.51%
|
-290.32%
|
-186.42%
|
-62.83%
|
-15.25%
|
Earnings before Tax (EBT)
1 |
-4.436
|
29.94
|
-2.28
|
-4.67
|
-4.178
|
-5.991
|
-9.813
|
-5.4
|
-5.509
|
-20.11
|
-7.8
|
-7
|
-5.65
|
-4.3
|
Net income
1 |
-5.804
|
19.74
|
-3.648
|
-6.038
|
-5.546
|
-7.344
|
-11.18
|
-6.768
|
-6.877
|
-21.48
|
-9.4
|
-8.667
|
-6.733
|
-6.267
|
Net margin
|
-617.45%
|
54.93%
|
-117.41%
|
-614.24%
|
-1,229.71%
|
-494.21%
|
-2,558.58%
|
-408.2%
|
-828.55%
|
-1,171.69%
|
-551.32%
|
-375.72%
|
-151.08%
|
-106.21%
|
EPS
2 |
-0.5100
|
1.670
|
-0.3200
|
-0.5300
|
-0.4800
|
-0.6400
|
-0.9800
|
-0.5900
|
-0.6000
|
-1.870
|
-0.8100
|
-0.7433
|
-0.5800
|
-0.5533
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/8/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/9/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/8/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/10/21
|
3/8/22
|
3/9/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
25.82
USD Average target price
57
USD Spread / Average Target +120.76% Consensus |
1st Jan change
|
Capi.
|
---|
| +39.57% | 300M | | -1.17% | 104B | | +2.87% | 97.47B | | +2.13% | 22.25B | | -14.77% | 21.68B | | -8.79% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|